| Artru, Pascal |
GASTFOX, NCT03006432: PHASE III RANDOMISED TRIAL TO EVALUATE FOLFOX WITH OR WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY FOR LOCALLY ADVANCED OR METASTATIC OESOPHAGO-GASTRIC CARCINOMA |
|
|
| Active, not recruiting | 3 | 507 | Europe, RoW | Oxaliplatin, 5Fluorouracil bolus, 5Fluorouracil continu, Docetaxel, Folinic Acid | Federation Francophone de Cancerologie Digestive, UNICANCER, GERCOR - Multidisciplinary Oncology Cooperative Group | OESOPHAGO-GASTRIC CARCINOMA | 12/25 | 12/25 | | |
| Active, not recruiting | 3 | 792 | Europe, Canada | Irinotecan, Campto, Folfox Protocol, acid folinic + oxaliplatine + 5-FU | UNICANCER, Canadian Cancer Trials Group, GONO GROUP | Colon Cancer (High-risk Stage III: pT4N1 or pT1 to 4 N2) | 06/25 | 06/27 | | |
| Not yet recruiting | 3 | 244 | NA | Avastin, 25 Mg/mL Intravenous Solution, Experimental group, Control group | University Hospital, Tours, CHU DE BESANCON, Gustave Roussy, Cancer Campus, Grand Paris, CHU de Clermont-Ferrand, CHU de Reims, CHU de Brest, AP-HP, Hôpital Pitié- Salpétrière, CHU de Rouen, Poitiers University Hospital, Institut Paoli-Calmettes, Rennes University Hospital, University Hospital, Toulouse, AP-HP, Hôpital Saint-Louis, HCL Hôpital Edouard Hériot, Centre Hospitalier Universitaire Dijon, Nantes University Hospital, Centre Hospitalier Universitaire, Amiens, Hôpital Privé Jean Mermoz, AP-HP, Hôpital Henri Mondor, AP-HP, Hôpital Paul Brousse, CHG de St-Malo, Polyclinique de Blois, University Hospital, Caen, CHU de Nancy | Unresectable Metastatic Colorectal Cancer | 10/28 | 10/29 | | |
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer |
|
|
| Recruiting | 3 | 711 | Europe, Canada, Japan, US, RoW | Dostarlimab, CAPEOX, FOLFOX | GlaxoSmithKline | Colonic Neoplasms, Neoplasms, Colon | 12/28 | 12/30 | | |
| Active, not recruiting | 2 | 288 | Europe, RoW | Irinotecan Liposomal Injection, Nal-IRI, 5-FU/LV, Nab-Paclitaxel, Gemcitabine | Federation Francophone de Cancerologie Digestive | Metastatic Pancreatic Cancer | 09/24 | 12/24 | | |
LAP-NET1, NCT05546853: Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma |
|
|
| Recruiting | 1 | 52 | Europe | NP137, Oxaliplatin, Irinotecan, Calcium levofolinate, 5 FU | University Hospital, Grenoble, NETRIS Pharma | Pancreatic Ductal Adenocarcinoma | 03/26 | 03/27 | | |
| Recruiting | N/A | 1500 | Europe | collection of biological samples | University Hospital, Toulouse | Adenocarcinoma, Carcinoma, Neoplasms | 01/35 | 02/35 | | |
| Recruiting | N/A | 103 | Europe | Blood Sample Collection | Jules Bordet Institute, Hoffmann-La Roche | Unresectable Locally Advanced Colorectal Cancer, Metastatic Colorectal Cancer, Candidate for Third-line or Subsequent Lines of Therapy | 01/26 | 07/26 | | |
NCT03694938: Detection of Brain Metastasis by MRI in Metastatic Colorectal Cancer Patients |
|
|
| Recruiting | N/A | 200 | Europe | Magnetic resonance imaging | Poitiers University Hospital | Metastatic Colon Cancer | 02/30 | 02/30 | | |
NCT04935853: Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study |
|
|
| Recruiting | N/A | 1350 | Europe | | GERCOR - Multidisciplinary Oncology Cooperative Group | Biliary Tract Cancer | 06/30 | 06/40 | | |
| Hautefeuille, Vincent |
GASTFOX, NCT03006432: PHASE III RANDOMISED TRIAL TO EVALUATE FOLFOX WITH OR WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY FOR LOCALLY ADVANCED OR METASTATIC OESOPHAGO-GASTRIC CARCINOMA |
|
|
| Active, not recruiting | 3 | 507 | Europe, RoW | Oxaliplatin, 5Fluorouracil bolus, 5Fluorouracil continu, Docetaxel, Folinic Acid | Federation Francophone de Cancerologie Digestive, UNICANCER, GERCOR - Multidisciplinary Oncology Cooperative Group | OESOPHAGO-GASTRIC CARCINOMA | 12/25 | 12/25 | | |
COLAGE, NCT03828227: QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters. |
|
|
| Active, not recruiting | 3 | 49 | Europe | OPTIMOX-bevacizumab, Folinic acid (FA)-5-fluorouracil (5-FU)-oxaliplatin [OPTIMOX], Avastin, Capecitabine plus bevacizumab, capecitabine | GERCOR - Multidisciplinary Oncology Cooperative Group | Elderly Patients, Metastatic Colorectal Cancer, Quality of Life | 11/23 | 09/24 | | |
ADAGE, NCT02355379: Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over |
|
|
| Recruiting | 3 | 774 | Europe | LV5FU2 or capectitabine, FOLFOX4 or XELOX, Observation, LV5FU2 or capecitabine | Federation Francophone de Cancerologie Digestive | Colonic Adenocarcinoma | 12/24 | 08/25 | | |
| Not yet recruiting | 3 | 244 | NA | Avastin, 25 Mg/mL Intravenous Solution, Experimental group, Control group | University Hospital, Tours, CHU DE BESANCON, Gustave Roussy, Cancer Campus, Grand Paris, CHU de Clermont-Ferrand, CHU de Reims, CHU de Brest, AP-HP, Hôpital Pitié- Salpétrière, CHU de Rouen, Poitiers University Hospital, Institut Paoli-Calmettes, Rennes University Hospital, University Hospital, Toulouse, AP-HP, Hôpital Saint-Louis, HCL Hôpital Edouard Hériot, Centre Hospitalier Universitaire Dijon, Nantes University Hospital, Centre Hospitalier Universitaire, Amiens, Hôpital Privé Jean Mermoz, AP-HP, Hôpital Henri Mondor, AP-HP, Hôpital Paul Brousse, CHG de St-Malo, Polyclinique de Blois, University Hospital, Caen, CHU de Nancy | Unresectable Metastatic Colorectal Cancer | 10/28 | 10/29 | | |
| Active, not recruiting | 2 | 176 | Europe | Trifluridine/Tipiracil, Lonsurf | GERCOR - Multidisciplinary Oncology Cooperative Group | Metastatic Colorectal Cancer | 11/23 | 11/24 | | |
TEDOPAM, NCT03806309: Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma |
|
|
| Recruiting | 2 | 106 | Europe | FOLFIRI, Leucovorin (Folinic Acid), Fluorouracil, Irinotecan, OSE2101, Tedopi | GERCOR - Multidisciplinary Oncology Cooperative Group, OSE Immunotherapeutics | Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer, Metastatic Cancer | 12/23 | 12/24 | | |
OPTIPRIME, NCT03584711: FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation |
|
|
| Active, not recruiting | 2 | 118 | Europe, RoW | FOLFOX + panitumumab | Federation Francophone de Cancerologie Digestive, Amgen | Metastatic Colorectal Cancer | 12/24 | 12/24 | | |
OESIRI, NCT03719924: Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma |
|
|
| Active, not recruiting | 2 | 106 | Europe | Onivyde, no other intervention name to add, Paclitaxel | Federation Francophone de Cancerologie Digestive, Shire | Squamous Cell Carcinoma | 11/24 | 04/25 | | |
POCHI, NCT04262687: Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate |
|
|
| Recruiting | 2 | 55 | Europe | Capecitabine, Oxaliplatin, Bevacizumab, Pembrolizumab | Federation Francophone de Cancerologie Digestive | Colorectal Cancer Metastatic, High Immune Infiltrate, Microsatellite Stable | 09/24 | 09/24 | | |
NEONEC, NCT04268121: Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas |
|
|
| Recruiting | 2 | 78 | Europe | Neoadjuvant treatment, cisplatin / cisplatinum, etoposide / vepesid, carbopatin / paraplatin, Adjuvant treatment | GERCOR - Multidisciplinary Oncology Cooperative Group, Fondation ARCAD | Neuroendocrine Carcinoma, Digestive Cancer | 01/34 | 06/34 | | |
Ibe2i-TIPCI, NCT05813418: Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment |
|
|
| Recruiting | N/A | 150 | Europe | blood retriewal | Centre Hospitalier Universitaire, Amiens, Central Hospital Saint Quentin | Immunotherapy, Immune Checkpoint Inhibitors, Immune-related Adverse Event, Predictive Biomarkers | 12/24 | 07/25 | | |
| Recruiting | N/A | 330 | Europe | Blood sampling to build population pharmacokinetics model | UNICANCER | Digestive Cancer, Metastatic Colorectal Cancer, Hepatocellular Carcinoma, GIST, Neuroendocrine Tumors | 08/26 | 06/27 | | |
NCT03694938: Detection of Brain Metastasis by MRI in Metastatic Colorectal Cancer Patients |
|
|
| Recruiting | N/A | 200 | Europe | Magnetic resonance imaging | Poitiers University Hospital | Metastatic Colon Cancer | 02/30 | 02/30 | | |
NCT04935853: Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study |
|
|
| Recruiting | N/A | 1350 | Europe | | GERCOR - Multidisciplinary Oncology Cooperative Group | Biliary Tract Cancer | 06/30 | 06/40 | | |
